Modulation of human cardiac function through 4 β-adrenoceptor populations

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 6, 1997, Pages 667-681

  Kaumann, Alberto J ^a   Molenaar, Peter ^b  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

1 , 2 3 Adrenoceptors; Arrhythmias; Human heart; Myocardial relaxation; Putative 4 adrenoceptor; Systole and diastole

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADENYLATE CYCLASE; ADRENALIN; ALPRENOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 4 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; BUPRANOLOL; CARAZOLOL; CARVEDILOL; DOBUTAMINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; METOLAZONE; METOPROLOL; NADOLOL; NORADRENALIN; PARTIAL AGONIST; PINDOLOL; PROPRANOLOL; RECEPTOR SUBTYPE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINTEROL;

DIASTOLE; HEART ARRHYTHMIA; HEART FUNCTION; HEART MUSCLE RELAXATION; HUMAN; INOTROPISM; MODULATION; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SYSTOLE;

ATRIAL FUNCTION; DIASTOLE; HEART; HUMANS; MYOCARDIAL CONTRACTION; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; SYSTOLE;

EID: 0030776329     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004999     Document Type: Review

References (114)

1. 2-adrenergic stimulation. Circulation 92:1612-1618
2. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alteration in sarcoplasmic reticulum gene expression in human heart failure. Circ Res 72:463-469
3. 3 and atypical β-adrenoceptors. Med Res Rev 14:663-729
4. Bearer CF, Knapp RD, Kaumann AJ, Schwartz TL, Birnbaumer L (1980) Iodohydroxybenzylpindolol: preparation, purification, localization of its iodine in the indole ring, and characterization as a partial agonist. Mol Pharmacol 17:328-338
5. 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. J Cell Biochem 58:464-473
6. 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289:223-228
7. Bers DM, Bridge HB (1989) Relaxation of rabbit ventricular muscle by Na-Ca exchange and sarcoplasmic reticulum pumping. Circ Res 65:334-342
8. Bers DM, Lederer WJ, Berlin JR (1990) Intracellular Ca transients in rat cardiac myocytes: role of Na-Ca exchange in excitation-contraction coupling. Am J Physiol 258:C944-C954
9. Beuckelmann DJ, Näbauer M, Erdmann E (1991) Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 23:929-937
10. Black J (1989) Drugs from emasculated hormones: the principle of synaptic antagonism. Science 245:486-493
11. Black J (1996) A personal view of pharmacology. Ann Rev Pharmacol Toxicol 36:1-33
12. Blinks JR (1967) Evaluation of the cardiac effects of several beta adrenergic blocking agens. Ann New York Acad Sci 139:673-685
13. 2+-release from sarcoplasmic reticulum by a cyclic AMP dependent mechanism. Pflügers Arch 415:276-288
14. Bond RA, Clarke DE (1988) Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the α- and β-subtypes. Br J Pharmacol 95:723-734
15. 2-adrenoceptor. Nature 374:272-276
16. Bond RA, Lefkowitz RJ (1996) The third beta is not a charm. J Clin Invest 98:241
17. 2-adrenoceptors in sheep cardiac ventricular muscle. J Mol Cell Cardiol 24:753-764
18. Na-Ca in cardiac myocytes. Science 248:376-378
19. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connel JB, Renlund DG, Volkmann K, Murray RNJ. Feldman AM (1991) Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic cardiomyopathy. Circulation 84:1024-1039
20. Bristow MR, Gilbert EM (1995) Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J 16 [Suppl F]:20-31
21. 1-receptor down-regulation in heart failure. Circ Res 59:297-309
22. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 307:205-211
23. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM (1990) β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82 [Suppl I]:12-25
24. 2-adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol 35:295-303
25. Buxton BF, Jones CR, Molenaar P, Summers RJ (1987) Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 92:299-310
26. 3-adrenergic receptor. J Pharmacol Exp Ther 271:1253-1258
27. 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal 6:457-465
28. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonist affinity of β-adrenergic antagonists. Mol Pharmacol 45:490-499
29. Del Castillo J, Katz B (1957) A study of curare action with an electric micromethod. Proc Roy Soc Ser B 146:339-356
30. 2-adrenoceptors in single myocytes from human ventricle. Circulation 88:854-863
31. 3-selective antagonist SR59230A. Br J Pharmacol 117:1374-1376
32. Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, Strosberg AD, Largis EE, Dutia MD, Bloom JD, Bass AS, Tankella TK, Cobuzzi A, Lai FM, Claus TH (1994) Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269:1000-1006
33. Drago GA, Colyer J (1994) Discrimination between two sites of phosphorylation on adjacent amino acids by phosphorylation site-specific antibodies to phospholamban. J Biol Chem 269:25073-25077
34. 2-adrenoceptors in the human atrioventricular conducting system: a comparison of patients with idiopathic dilated cardiomyopathy and ischemic heart disease. J Mol Cell Cardiol 26:313-323
35. 3-adrenergic receptor. Science 245:1118-1121
36. Eschenhagen T (1996) Role of inhibitory G proteins for the control of catecholamine-induced cardiac arrhythmias. Naunyn-Schmiedeberg's Arch Pharmacol 354[Suppl]:R 1
37. Fabiato A, Fahiato F (1979) Calcium and cardiac excitation-contraction coupling. Ann Rev Physiol 41:473-484
38. Feldman AM, Gates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C (1988) Increase of the 40,000 mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82:189-197
39. 1-adrenergic stimulation in vitro. J Cardiovasc Pharmacol 25:134-141
40. Freestone N, Kaumann AJ (1997) Activation of an atypical β-adrenoceptor increases calcium and can elicit arrhythmias in rat atrial cardiomyocytes. Pharmacologist 39:74 (abstr 292)
41. 3-adrenoceptors in human ventricular cells: (abstract 3065). Circulation 92:639
42. 3-adrenergic receptor in human heart. J Clin Invest 98:556-562
43. 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 331:60-70
44. Granneman JG (1992) Effects of agonist exposure on the coupling of beta I and beta3 adrenergic receptors to adenylyl cyclase in isolated adipocytes. J Pharmacol Exp Ther 261:638-642
45. 2-receptors display subtype-selective coupling to Gs. Mol Pharmacol 41:889-893
46. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocycte. Am J Physiol 270:H1159-H1164
47. 2-adrenoceptors in human atrial myocardium. Circ Res 66:1610-1623
48. 1-antagonist treatment. Circ Res 69:959-964
49. Katz B, Thesleff S (1957) A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J Physiol 138:63-80
50. Kaumann AJ (1973) Adrenergic receptors in heart muscle. Two different mechanisms of β blockers as partial agonists. International Union of Biochemistry, Symposium 52, Acta Physiol LatAm 23:235-236
51. Kaumann AJ (1983) Cardiac β-adrenoceptors. Experimental view-points. Z Kardiol 72:63-82
52. 2-adrenoceptors activated by (-)-adrenaline in rat sinoatrial node. Naunyn-Schmiedeberg's Arch Pharmacol 333:73-76
53. Kaumann AJ (1989) Is there a third heart β-adrenoceptor? Trends Pharmacol Sci 10:316-320
54. Kaumann AJ (1996) (-)-CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:93-98
55. Kaumann AJ, Blinks JR (1980a) Stimulant and depressant effects of β-adrenoceptor blocking agents on isolated heart muscle. A positive inotropic effect not mediated through adrenoceptors. NaunynSchmiedeberg's Arch Pharmacol 311:205-218
56. Kaumann AJ, Blinks JR (1980b) β-Adrenoceptor blocking agents as partial agonists. Dissociation of stimulation and blockade. Naunyn-Schmiedeberg's Arch Pharmacol 311:237-248
57. Kaumann AJ, Freestone N (1997) Atypical β-adrenoceptor activation by (-)-CGP 12177 increases cytosolic calcium in rat ventricular myocytes. Pharmacologist 39:74 (abstr 293)
58. 2-Adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 335:403-411
59. Kaumann AJ, Lynham JA (1997) (-)-CGP 12177 stimulates cyclic AMP-dependent protein kinase in rat atria through an atypical β-adrenoceptor. Br J Phamacol 120:1187-1189
60. Kaumann AJ, Molenaar P (1996) Differences between the third cardiac β-adrenoceptor and the colonic β-adrenoceptor in the rat. Br J Pharmacol 118:2085-2098
61. 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn-Schmiedeberg's Arch Pharmacol 348:536-540
62. 4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch Pharmacol 349:331-336
63. Kaumann AJ, Birnbaumer L, Wittmann R (1978) Heart β-adrenoceptors. In: Birnbaumer L, O'Malley BWO (eds) Hormone receptors. Academic Press, New York, pp 133-177
64. Kaumann AJ, McInerny TK, Gilmour DP, Blinks JR (1980) Comparative assessment of β-adrenoceptor blocking agents as simple competitive antagonists in isolated heart muscle. Naunyn-Schmiedeberg's Arch Pharmacol 311:219-236
65. 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 10 [Suppl B]:29-37
66. Kaumann AJ, Lemoine H, Schwederski-Menke U, Ehle B (1989b) Relations between β-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Acute desensitization and comparison with feline ventricle. Naunyn-Schmiedeberg's Arch Pharmacol 339:99-112
67. 2-adrenoceptors in human ventricular myocardium from failing hearts hastens the onset of relaxation. Br J Pharmacol 105:283P
68. 2-adrenoceptors. Pharmacol Commun 6:215-222
69. 2-Adrenoceptor-mediated relaxation and phosphorylation of phospholamban in human ventricle. Proceedings of the 44th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Brisbane, 4-7 August, abstract 125
70. 2-Adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. Mol Cell Biochem 163/164:113-123
71. 3-adrenoceptors and coupled to a cyclic AMP-dependent pathway in human and rat myocardium. Br J Pharmacol (in press)
72. Koch WJ, Milano CA, Lefkowitz RJ (1996) Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Circ Res 78:511-516
73. Krause E-G, Bartel S, Karczewski P, Kuschel M, Burrell KM, Molenaar P, Kaumann AJ (1996) In: Myocardial functions: pathophysiological, methodological and clinical aspects. III. International Conference Padova October 23-25 Proceedings
74. 3-adrenergic receptor mRNA in man. J Clin Invest 91:344-349
75. 2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes. Circ Res 76:40-52
76. Le Grand B, Hatem S, Deroubaix E, Couetil J-P, Coraboeuf E (1994) Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 28:548-556
77. Le Grand B, Hatem S, Deroubaix E, Couetil JP, Coraboeuf E (1991) Calcium current depression in isolated human atrial myocytes after cessation of chronic treatment with calcium antagonists. Circ Res 69:292-300
78. 2-adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP. Naunyn-Schmiedeberg's Arch Pharmacol 344:56-69
79. 2-adrenergic receptors. Proc Natl Acad Sci USA 90:10798-10802
80. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR (1994) Clinical relevance of inverse agonism and nucleotide binding properties of β-adrenergic receptor blocking agents. Circulation 90 [Suppl 1] 1-543
81. Malinowska B, Schlicker E (1996) Mediation of the positive chronotropic effects of CGP 12177 and cyanopindolol in the pithed rat by atypical β-adrenoceptors. Br J Pharmacol 117:943-949
82. 3) - β-adrenoceptors. Pharmacol Commun 6:253-258
83. Man'Int Veld AJ, Schalekamp MADH (1981) Pindolol acts as a betaadrenoceptor agonist in orthostatic hypotension: therapeutic implications. Br Med J 282:929-931
84. 1-adrenoceptors Am J Physiol 271H 1465-H 1472
85. 2+ release channels and their regulation by endogenous effectors. Ann Rev Physiol 56:485-508
86. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85:305-309
87. Mewes T, Dutz S, Ravens U, Jakobs KH (1993) Activation of calcium currents in cardiac myocytes by empty β-adrenoceptors. Circulation 88:2916-2922
88. 2-adrenergic receptor. Science 264:582-586
89. 2-adrenoceptors in human atrium. Proc Aust Soc Clin Exp Pharmacol Toxicol 3:39
90. 2-adrenoceptors in guinea-pig atrioventricular conducting system. J Mol Cell Cardiol 22:483-495
91. 3-adrenoceptors. Br J Pharmacol (in press)
92. Mudiña-Weilenmann C, Vittone L, Ortale M, Chiappe de Cingolani G, Mattiazi A (1996) Immunodetection of phosphorylation sites gives new insight into the mechanisms underlying phospholamban phosphorylation in the heart. J Biol Chem 271:33561-33567
93. 3-adrenergic receptor is resistant to short-term agonist-promoted desensitization. Mol Pharmacol 43:548-555
94. Neumann J, Schmitz W, Scholz H, Meyerink LV, Doring V, Kalma P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet II:936-937
95. Reuter H (1983) Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 301:569-574
96. 2+-regulatory site of bovine cardiac troponin. J Biol Chem 257:260-263
97. 2-adrenergic receptor is associated with reduced phospholamban protein. J Clin Invest 97:1618-1623
98. 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375-7380
99. Sanders L, Lynham JA, Bond B, del Monte F, Harding SE, Kaumann AJ (1995) Sensitization of human 5-HT4 receptors by chronic β blocker treatment. Circulation 92:2526-2539
100. 2 receptor systems in human atrium. Naunyn-Schmiedeberg's Arch Pharmacol 353:661-670
101. Sarsero D, Molenaar P, Kaumann AJ (1996a) The human cardiac atypical β-adrenoceptor stimulates a cyclic AMP-dependent pathway. J Mol Cell Cardiol 288:A274
102. Sarsero D, Molenaar P, Kaumann AJ (1996b) Stimulation of the "putative β4-adrenoceptor" causes positive inotropic effects and hastens relaxation in human atrium and ventricle through a cyclic AMP-dependent pathway. Proc Aust Soc Clin Exp Physiol Pharmacol 3:38
103. Sarsero D, Molenaar P, Kaumann AJ (1997) (-)-[3H]-CGP 12177 labels atypical β-adrenoceptors (βAR) in rat atrium. Pharmacologist 39:39 (abstr 104)
104. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92:3220-3228
105. Trautwein W, Hescheler J (1990) Regulation of cardiac L-type calcium current by phosphorylation and G proteins. Ann Rev Physiol 52:257-274
106. 1adrenergic receptors in failing human heart. Circulation 87:454-463
107. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Gross FG, Hjalmarson A (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446
108. Walter M, Lemoine H, Kaumann AJ (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig: role of β-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn-Schmiedeberg's Arch Pharmacol 327:159-175
109. Wegener AD, Simmerman HKB, Lindemann JP, Jones LR (1986) Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to β-adrenergic stimulation. J Biol Chem 261:13333-13341
110. 2+ current in single rat ventricular cells. Circ Res 73:286-300
111. 2+ dynamics, contractility or phospholamban phosphorylation. J Biol Chem 269:1-6
112. 2-adrenoceptor to pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47:322-329
113. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR (1996) Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 17 [Suppl B]:8-16
114. Zhang R, Zhao J, Mandveno A, Potter JD (1995) Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res 76:1028-1038